Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Peptide vaccine OCV-C02 safe and well tolerated in metastatic colorectal cancer patients

Jan. 24, 2017

Merck KGaA and Domain Therapeutics announce license and collaboration agreement

Jan. 24, 2017

First patient dosed in phase Ib study of OncoMed's brontictuzumab

Jan. 23, 2017

Telix signs product collaboration and purchase option agreement with Atlab

Jan. 20, 2017

Immunomedics presents new data for IMMU-132

Jan. 19, 2017

Celsion reports data from fourth cohort of OVATION study

Jan. 18, 2017

Anti-HER2 DC1 vaccination is a safe and immunogenic in HER2+ patients

Jan. 18, 2017

CytomX initiates first-in-human study of CX-072 to treat solid tumors and lymphomas

Jan. 17, 2017

AstraZeneca updates status of durvalumab trials in first-line NSCLC

Jan. 17, 2017

European Commission confirms orphan drug designation for TB-403 for medulloblastoma

Jan. 17, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...